DrugPatentWatch Database Preview
Details for Patent: 6,858,650
Which drugs does patent 6,858,650 protect, and when does it expire?
Patent 6,858,650 protects TOVIAZ and is included in one NDA.
This patent has seventy-eight patent family members in twenty-nine countries.
Summary for Patent: 6,858,650
| Title: | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
| Abstract: | The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products. The method is in particular characterized by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyr ate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyra te ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is R-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester. |
| Inventor(s): | Meese; Claus (Monheim, DE) |
| Assignee: | Schwarz Pharma AG (DE) |
| Application Number: | 10/130,214 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,858,650 |
|
Patent Claim Types: see list of patent claims | Compound; Formulation; Use; |
Drugs Protected by US Patent 6,858,650
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | TOVIAZ | fesoterodine fumarate | TABLET, EXTENDED RELEASE;ORAL | 022030-001 | Oct 31, 2008 | AB | RX | Yes | No | Start Trial | Start Trial | Y | TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY | Start Trial | ||
| Pfizer | TOVIAZ | fesoterodine fumarate | TABLET, EXTENDED RELEASE;ORAL | 022030-002 | Oct 31, 2008 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,858,650
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Germany | 199 55 190 | Nov 16, 1999 |
| PCT Information | |||
| PCT Filed | November 15, 2000 | PCT Application Number: | PCT/EP00/11309 |
| PCT Publication Date: | May 25, 2001 | PCT Publication Number: | WO01/35957 |
International Family Members for US Patent 6,858,650
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 286872 | Start Trial | |||
| Austria | 337293 | Start Trial | |||
| Austria | 395056 | Start Trial | |||
| Australia | 2666701 | Start Trial | |||
| Australia | 778132 | Start Trial | |||
| Brazil | 0015610 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
